NutritionJuly 21, 2026·4 min read
By the CIRRUS Editorial Team — how we write and source this
Omega-3 fatty acids and lung inflammation: what the evidence actually supports
Omega-3s get credited with broad anti-inflammatory benefits across nearly every condition. What the research specific to respiratory inflammation actually shows, separated from the general supplement marketing.
Omega-3 fatty acids — primarily EPA and DHA, found concentrated in fatty fish and available as supplements — have a genuinely well-established general anti-inflammatory mechanism, working in part by competing with pro-inflammatory omega-6-derived compounds in the body's inflammatory signaling pathways. That mechanism is real and reasonably well understood at the cellular level, which is different from saying every downstream clinical claim built on top of it has equally strong supporting evidence.
For respiratory inflammation specifically, the evidence is more mixed than the general anti-inflammatory framing suggests: some studies show modest benefit in asthma symptom control and inflammatory markers with higher-dose omega-3 supplementation, while others show no meaningful clinical difference, and the overall body of evidence hasn't produced the kind of clear, consistent effect size that would support a strong blanket recommendation for omega-3 supplementation specifically to manage COPD or asthma symptoms.
Where the evidence is considerably stronger and better established: omega-3 intake's cardiovascular benefits, particularly around triglyceride reduction, are well-supported by larger and more consistent trial data than the respiratory-specific claims. Since cardiovascular and respiratory disease frequently coexist and interact — the heart-lung connection covered elsewhere — a patient managing both conditions may reasonably benefit from omega-3 intake through the cardiovascular pathway even where the direct respiratory evidence is less definitive.
The practical takeaway: dietary omega-3 intake through fatty fish a couple of times a week is a reasonable, low-risk recommendation supported by the stronger general cardiovascular evidence, but anyone considering higher-dose supplementation specifically chasing a respiratory inflammation benefit should treat that as a less certain bet than the marketing around omega-3 supplements sometimes implies, and it's worth discussing with a physician rather than assuming it stands in for actual respiratory treatment.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.